Back

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 1

- 22 January 2025 - 1 mins read

The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).

Related Clinical Trials

Effects of triptorelin when given every 6-months under the skin to adult males with cancer in the prostate
22 January 2025 1 mins read

Effects of triptorelin when given every 6-months under the skin to adult males with cancer in the prostate
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
22 January 2025 1 mins read

Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
22 January 2025 1 mins read

A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines
A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.
22 January 2025 1 mins read

A Study to Assess the Safety and Efficacy of IPN10200 of in Adult Participants With Upper Limb Spasticity.
Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
22 January 2025 1 mins read

Study to evaluate the safety and activity (including distribution) of 177Lu-3BP-227 in subjects with solid tumours expressing neurotensin receptor type 1.
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
22 January 2025 1 mins read

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
22 January 2025 1 mins read

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic...
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
22 January 2025 1 mins read

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
22 January 2025 1 mins read

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
22 January 2025 1 mins read

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)